What are the various formulations of epinephrine (adrenaline) and their clinical indications?

Types of Epinephrine Formulations and Clinical Applications

Epinephrine is available in two primary concentrations—1:1000 (1 mg/mL) and 1:10,000 (0.1 mg/mL)—with the route of administration and concentration selection being critical to prevent fatal dosing errors. 1

Primary Formulations

1:1000 Concentration (1 mg/mL)

This is the standard concentration for intramuscular (IM), subcutaneous (SC), and nebulized administration. 1, 2

Clinical indications include:

• Anaphylaxis (IM route preferred): 0.01 mg/kg (maximum 0.3-0.5 mg), repeated every 5-20 minutes as needed 1, 3

  • The IM route into the anterolateral thigh is superior to subcutaneous administration, producing more rapid and reliable peak plasma concentrations 3, 4
  • Autoinjectors deliver fixed doses: 0.3 mg (adult), 0.15 mg (pediatric), or 0.1 mg (infant formulations) 3, 4

• Severe asthma exacerbation (SC): 0.01 mg/kg of 1:1000 solution (maximum 0.3-0.5 mg), may repeat every 20 minutes up to 3 doses 1

• Croup/laryngotracheobronchitis (nebulized): 0.5 mL/kg of 1:1000 solution (maximum 5 mL) administered by nebulizer 1

1:10,000 Concentration (0.1 mg/mL)

This dilute concentration is used exclusively for intravenous (IV) or intraosseous (IO) administration to reduce the risk of fatal arrhythmias. 1, 5

Clinical indications include:

• Cardiopulmonary resuscitation (IV/IO):

  • Newborns: 0.01-0.03 mg/kg of 1:10,000 solution 1
  • Older infants/children: 0.01 mg/kg (maximum 1 mg), repeated every 3-5 minutes 1
  • Adults: Standard ACLS dosing of 1 mg every 3-5 minutes 6

• Anaphylactic shock with IV access: 0.05-0.1 mg (5-10% of cardiac arrest dose) administered slowly 3, 5

Racemic Epinephrine (2.25% solution)

A specialized nebulized formulation containing both D and L isomers, used specifically for acute airway edema. 1

• Dosing: 0.05 mL/kg (maximum 0.5 mL) in 2 mL normal saline by nebulizer
• Many institutions use a standard 0.5 mL dose for all patients
• If unavailable, L-epinephrine 1:1000 can substitute at 0.5 mL/kg (maximum 5 mL) 1

Continuous Infusion Formulations

For refractory shock or persistent anaphylaxis, epinephrine infusions are prepared by diluting to specific concentrations:

• Standard preparation: 1 mg (1 mL of 1:1000) in 250 mL D5W = 4 mcg/mL concentration 5

  • Infuse at 1-4 mcg/min initially, titrate to maximum 10 mcg/min 5

• Alternative preparation: 1 mg in 100 mL saline = 10 mcg/mL (1:100,000 solution) 5

  • Initial rate 30-100 mL/h (5-15 mcg/min), titrated to effect 5

• Pediatric dosing: 0.1-1.0 mcg/kg/min for shock after volume resuscitation, may increase to 5 mcg/kg/min 1

• Post-cardiac arrest: 0.1-0.5 mcg/kg/min (in 70-kg adult: 7-35 mcg/min) 6

Critical Safety Considerations

The most common fatal error is confusing 1:1000 with 1:10,000 concentrations, resulting in 10-fold overdosing when IV administration is intended. 1, 5

• Never administer 1:1000 concentration intravenously except in dire cardiac arrest situations with extreme caution
• IV epinephrine should only be given during cardiac arrest or profound hypotension unresponsive to multiple IM doses and volume resuscitation 5
• Continuous hemodynamic monitoring is mandatory when using IV epinephrine 5
• Extravasation causes severe tissue necrosis; treat immediately with phentolamine 0.1-0.2 mg/kg (maximum 10 mg) diluted in 10 mL saline, injected intradermally at the site 1, 6

Route-Specific Algorithms

For anaphylaxis without cardiac arrest:

1. First-line: IM 1:1000 into anterolateral thigh 3
2. If IV access present and severe shock: Consider IV 1:10,000 at 0.05-0.1 mg 3
3. If persistent after 2-3 IM doses: Initiate continuous infusion 4, 7

For cardiac arrest:

1. Use only 1:10,000 concentration IV/IO 1
2. High-dose epinephrine (0.1 mg/kg) is no longer recommended routinely, except for beta-blocker poisoning 1

For airway emergencies:

1. Croup/laryngeal edema: Nebulized racemic epinephrine or 1:1000 1
2. Severe asthma unresponsive to beta-agonists: SC 1:1000 1

The evidence consistently demonstrates that prompt administration by the appropriate route with correct concentration is more important than any other intervention in preventing anaphylaxis mortality. 3, 4, 8